Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

BACKGROUND: NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant. METHODS: We initiated a randomized, placebo-controlled, phase 1–2 trial to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Keech, Cheryl, Albert, Gary, Cho, Iksung, Robertson, Andreana, Reed, Patricia, Neal, Susan, Plested, Joyce S., Zhu, Mingzhu, Cloney-Clark, Shane, Zhou, Haixia, Smith, Gale, Patel, Nita, Frieman, Matthew B., Haupt, Robert E., Logue, James, McGrath, Marisa, Weston, Stuart, Piedra, Pedro A., Desai, Chinar, Callahan, Kathleen, Lewis, Maggie, Price-Abbott, Patricia, Formica, Neil, Shinde, Vivek, Fries, Louis, Lickliter, Jason D., Griffin, Paul, Wilkinson, Bethanie, Glenn, Gregory M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494251/
https://www.ncbi.nlm.nih.gov/pubmed/32877576
http://dx.doi.org/10.1056/NEJMoa2026920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494251/
https://www.ncbi.nlm.nih.gov/pubmed/32877576
http://dx.doi.org/10.1056/NEJMoa2026920

Ejemplares similares